Hikma highlights FDA-linked opportunity, shares steady on London trade

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 18:46.

Hikma Pharmaceuticals PLC (GB00B128J450) sits in focus on the London Stock Exchange today. The FTSE 250-listed generics specialist trades near 1,490 pence per share, reflecting a cautious but stable view of the U.K.-listed stock.

What MarketScreener reports

MarketScreener data show Hikma shares at 1,490 pence on 23 June 2026, up 0.20 percent from the previous close as 58,267 shares change hands on the London Stock Exchange. The ticker HIK remains one of the more closely watched names in the European generics segment alongside peers such as GSK in broader pharma.

The same MarketScreener overview highlights Hikma’s role across branded, injectables and generics, with operations in more than 50 countries including the U.S., Europe, North Africa and the Middle East. For investors, this geographic spread and business mix provide diversification in revenue streams, even though pricing pressure in U.S. generics remains a persistent theme.

Legal and regulatory backdrop in the U.S.

Recent news flow has underlined Hikma’s legal positioning in the key U.S. market. On 4 June 2026, MarketScreener cited a Supreme Court ruling siding with Hikma in a patent infringement dispute with Amarin, related to "skinny label" use for generic versions of the fish-oil-based cholesterol drug Vascepa. This decision reduces the immediate risk of major damages and clarifies how generics can be marketed without infringing branded indications.

The patent dispute outcome helps Hikma preserve its ability to commercialize certain generic cardiovascular therapies in the U.S. without bearing the cost of a large settlement. While the ruling does not remove all litigation risk for the sector, it offers a clearer path for Hikma and peers when structuring product labels and marketing materials in line with FDA approvals and patent law.

In parallel, MarketScreener notes Hikma’s interest in FDA-related developments such as the approval of Guardant360 Liquid CDx, a liquid biopsy companion diagnostic. Although the test is owned by Guardant Health rather than Hikma, the broader trend of more sophisticated diagnostics feeds into demand for oncology and specialty therapies, an area where generics and injectables manufacturers can win supply contracts and tenders.

Tuesday focus on analyst views

On Tuesday, the consensus picture for Hikma is central for investors weighing the stock. MarketScreener’s London quote page aggregates views from multiple houses on the HIK shares, providing estimates on earnings, margins and cash generation that frame the valuation at around 1,490 pence per share. These consensus numbers typically compare Hikma with larger U.K. pharma names such as GSK, albeit in a more focused generics niche.

Analysts generally monitor Hikma’s exposure to U.S. generics, its injectables portfolio and branded products in MENA markets when setting price targets and recommendations. The recent Supreme Court win against Amarin is likely to be reflected in updated research notes, as it reduces tail risk tied to patent litigation and may support assumptions on future U.S. sales volumes and profitability.

For investors, the combination of a diversified geographic footprint and clarity around a key U.S. legal case offers a more robust basis for comparing Hikma with both European peers and global generics names covered by international houses such as UBS or Goldman Sachs, even if specific target changes have not been highlighted publicly in the latest daily news feeds.

The products behind Hikma

Hikma’s business rests on three main units: Branded, Injectables and Generics. In injectables, the company supplies hospital-use sterile products, including antibiotics, anesthesia agents and oncology therapies in markets such as the U.S., Europe and MENA. The generics unit, which includes cardiovascular and respiratory drugs, has been central in the U.S. litigation around "skinny label" promotion that recently reached the Supreme Court.

Where the Hikma shares trade

The Hikma shares (GB00B128J450) trade on 2026-06-23 at 1,490.00 pence on the London Stock Exchange, according to MarketScreener’s latest quote. The London listing gives international investors direct exposure to the company’s global generics and injectables franchises without using ADRs or local MENA exchanges.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources cited and considered reliable at the time of publication, but may change without notice.